Kalaris Therapeutics, Inc.
KLRS
$5.83
-$0.02-0.34%
NASDAQ
| 12/31/2023 | |||||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 3.17M | ||||
| Total Receivables | -- | ||||
| Inventory | -- | ||||
| Prepaid Expenses | 164.00K | ||||
| Finance Division Loans and Leases Current | -- | ||||
| Total Finance Division Other Current Assets | -- | ||||
| Other Current Assets | -- | ||||
| Total Current Assets | 3.33M | ||||
|
|
|||||
| Total Current Assets | 3.33M | ||||
| Net Property, Plant & Equipment | -- | ||||
| Long-term Investments | -- | ||||
| Goodwill | -- | ||||
| Total Other Intangibles | -- | ||||
| Finance Div Loans & Leases LT | -- | ||||
| Total Finance Div Other LT Assets | -- | ||||
| Total Other Assets | -- | ||||
| Total Assets | 3.33M | ||||
|
|
|||||
| Total Accounts Payable | 2.36M | ||||
| Total Accrued Expenses | 1.00M | ||||
| Short-term Debt | -- | ||||
| Current Portion of Long-Term Debt/Capital Leases | -- | ||||
| Finance Division Debt Current | -- | ||||
| Total Finance Division Other Current Liabilities | 579.00K | ||||
| Total Other Current Liabilities | 579.00K | ||||
| Total Current Liabilities | 3.94M | ||||
|
|
|||||
| Total Current Liabilities | 3.94M | ||||
| Long-Term Debt | -- | ||||
| Short-term Debt | -- | ||||
| Capital Leases | -- | ||||
| Finance Division Debt Non Current | -- | ||||
| Total Finance Division Other Non Current Liabilities | -- | ||||
| Total Other Liabilities | -- | ||||
| Total Liabilities | 3.94M | ||||
|
|
|||||
| Common Stock & APIC | 2.38M | ||||
| Retained Earnings | -47.39M | ||||
| Treasury Stock & Other | -- | ||||
| Total Common Equity | -45.02M | ||||
|
|
|||||
| Preferred Stock Redeemable | -- | ||||
| Preferred Stock Non Redeemable | -- | ||||
| Preferred Stock Convertible | 44.41M | ||||
| Preferred Stock, Others | -- | ||||
| Total Preferred Equity | 44.41M | ||||
|
|
|||||
| Total Common Equity | -45.02M | ||||
| Total Preferred Equity | 44.41M | ||||
| Total Minority Interest | -- | ||||
| Total Equity | -609.00K | ||||
|
|
|||||